Chang Zheng Hospital Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01596855
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Changzheng-Cinkate | Chang Zheng Hospital

Active Ingredients

Drugs in Phase 2 Trials (4)

epoetin (Epogen) (1 trial)

leflunomide (arava) (1 trial)

roxadustat (1 trial)

vitamin b13 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Viremia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4